Project no. 832915/30000 TICK/SAI
Exhibit 10.25
| Project no. 832915/30000 TICK/SAI |
Funding contract
agreed between
Österreichische Forschungsförderungsgesellschaft mbH (FFG)
as funding donor
and
ARSANIS Biosciences GmbH
XXXXXX-XXXXXXXXXX-XXXXX 0 0000 XXXXXX
Company register number FN 354305 m
as funding recipient.
1 Awarding of the funding
| 1.1 | On the basis of the funding application “Development of human monoclonal antibody based product against severe hospital associated bacterial infections” submitted via eCall on 5/12/2011 and based on the professional decision of the advisory board during the session of 6/28/2011, a funding for the following project is awarded: | |||
| Project number: | 832915 | |||
| eCall number: | 2447334 | |||
| Project name (subject of the agreement): | ||||
| Development of human monoclonal antibody based product against severe hospital associated bacterial infections | ||||
| Program: | Basic program | |||
./2
| Österreichische Forschungsförderungsgesellschaft mbH Xxxxxxxxxxx 0 0000 Xxxxxx |
Tel +43(0)5 7755-0 Fax+00 (0)0 0000-00000 xxx.xxx.xx, xxxxxx@xxx.xx FN 252263a HG Vienna |
| Page 2 | Project no. 832915/30000 TICK/SAI |
2 Project duration
| 2.1 | The overall project duration begins on 5/13/2011 and ends on 5/31/2015. |
| 2.2 | The funding of the entire project by the FFG is dependent on the results discernible in the submitted reports, the continued fulfillment of the evaluation and decision criteria, the budget available to the funding donor, as well as a renewed positive funding decision. |
3 Funding period
| 3.1 | The objective funding period of the project begins on 5/13/2011 as the acceptance deadline and ends on 5/31/2012. |
4 Type and level of funding
| 4.1 | The funding is provided in the following form for the funding period specified in section 3: |
| Funding form |
Amount up to max. | |||
| FFG grant (HT BMWFJ) |
EUR | 661,500.00 | ||
| FFG loan |
EUR | 529,000.00 | ||
| Loan conditions | ||
| Interest rate | 2.0% p.a. on current account basis | |
| Repayment date: | on 6/30/2020 | |
| Repayment amount: | EUR 529,000.00 | |
| Interest and loan collection: | in direct debit | |
| Interest stipulation: | half-yearly in retrospect or on loan maturity | |
| 4.2 | The subsidized financing of the project amounts to 70.0% of the applicable and eligible project costs. The rest of the project cost funding is the responsibility of the funding recipient. Based on the planning data, the funding cash value amounts to EUR 765,607.00, that is 45.0% related to the eligible costs according to point 5.1. |
| 4.3 | The maximum funding cash value according to the applicable community guidelines for state R&D aid amounts to 45.0%. |
| 4.4 | The consequence of the shortfall of the eligible project costs is an aliquot reduction of the funding. |
| 4.5 | The eligible project costs according to section 5 as well the costs reported through interim and final settlements do not represent any cost acknowledgment before an assessment by the FFG. The final amount of the eligible total project costs as well as the funding are determined only after completion of the project during invoice verification. |
./3
| Österreichische Forschungsförderungsgesellschaft mbH Xxxxxxxxxxx 0 0000 Xxxxxx |
Tel +43(0)5 7755-0 Fax+00 (0)0 0000-00000 xxx.xxx.xx, xxxxxx@xxx.xx FN 252263a HG Vienna |
| Page 3 | Project no. 832915/30000 TICK/SAI |
5 Eligible costs
| 5.1 | The funding is subject to the following eligible project costs: |
| Personnel costs |
EUR | 1,000,000.00 | ||
| R&D infrastructure use |
EUR | 57,000.00 | ||
| General and material costs |
EUR | 547,300.00 | ||
| Third-party services |
EUR | 39,000.00 | ||
| Travel expenses |
EUR | 20,000.00 | ||
| Patent costs |
EUR | 38,000.00 | ||
|
|
|
|||
| Total eligible costs |
EUR | 1,701,300.00 |
| 5.2 | Eligible costs are all those costs and expenses attributable to the project that result directly, actually and additionally from the usual operating costs for the duration of the funded research activity. Additional supplementary provisions to the eligible costs can arise from FFG guidelines and from the “guidelines for handling project costs in funding applications”. |
| 5.3 | Substantial changes to the cost structure require the prior written approval of the FFG. |
| 5.4 | The sales tax levied on the costs of the service is not eligible. In so far as this sales tax demonstrably and finally is to be borne by the funding recipient and consequently no pre-tax deduction is applicable for him/her, it is taken into account as an eligible cost component. The—in whatever way—recoverable sales tax is not eligible, if the funding recipient does not get it back. If the tax office regards a grant not as a taxable service of the funding recipient to the funding donor according to BGBI no. 663 of the 1994 sales tax, but as contractual remuneration and sales tax is thus payable to the tax office by the funding recipient, the contractual remuneration is to be regarded as gross remuneration. An additional separate sales tax settlement is—for whatever legal reason—excluded. |
| 5.5 | If the amortization period of an item (section 285 ABGB), which is purchased to carry out the project, exceeds the funding period, the depreciation costs are eligible in the manner specified according to the FFG basis programs guidelines and in the “guidelines for handling the project costs in funding requests and reports”. |
| 5.6 | The funding means of the funding donor must not be used for the creation of reserves and provisions according to BGBI no. 400 of the 1988 income tax law. The funding means must be used only for the services and objectives set out in the funding request. |
| 5.7 | Recognized eligible costs are those which have arisen after receipt of the funding request. |
| 5.8 | The costs incurred by the funding recipient or his/her partners from preparation of the contract, or any transfer charges, must be borne by these parties and do not constitute eligible costs. |
./4
| Österreichische Forschungsförderungsgesellschaft mbH Xxxxxxxxxxx 0 0000 Xxxxxx |
Tel +43(0)5 7755-0 Fax+00 (0)0 0000-00000 xxx.xxx.xx, xxxxxx@xxx.xx FN 252263a HG Vienna |
| Page 4 | Project no. 832915/30000 TICK/SAI |
| 5.9 | The funding donor reserves the right to defer, reduce or suspend payment of funding, if and as long as circumstances are such that the orderly execution of the sponsored project appears not to be guaranteed (e.g. the cost justification is not provided as planned). |
6 Project-specific conditions and requirements
| 6.1 | Project-specific special conditions and requirements |
| 1. | Before payment of the 1st installment, a cooperation agreement signed by the company and regulating cooperation and particularly the exploitation rights to development must be signed. |
| 2. | Before payment of the 1st installment, a mutually signed cooperation contract with the company Arsanis Inc must be signed that regulates cooperation and particularly the exploitation rights to development. The economic exploitation of the project results must occur predominantly in Austria. It must also be ensured that all patent rights relevant for the project are to be made available to Arsanis Biosciences GmbH according to FFG guidelines. |
| 3. | Before payment of the 2nd installment, installment, Adimab LLC must provide evidence of the preparation of at least two monoclonal antibodies against E. coli and S. aureus. |
| 4. | Before payment of the 2nd installment, installment, evidence of the establishment of in vitro models for testing monoclonal antibodies must be provided. |
| 5. | The personnel and travel costs have generally been reduced. |
| 6. | The costs for the Strategic Board must be settled as overheads via the personnel costs overhead rate. |
7 Payment of the funding
| 7.1 | Payment of the 1st installment in the amount of 50% of the promised funding means follows after completion of the funding contract and fulfillment of the conditions and requirements agreed in Article 6. |
Payment of the second installment in the amount of 30% follows after approval of an interim report and an interim settlement, where 50% of the approved total costs must be shown, as well as after fulfillment of the conditions and requirements agreed in Article 6.
Payment of the final installment in the amount of 20% of total guaranteed funding means follows after fulfillment of the conditions and requirements (final settlement, final reports, etc.) and after inspection and approval of the usage certificate (relief) by the FFG.
| 7.2 | The transfer is made to the following account of the funding recipient |
Account owner: ARSANIS Biosciences GmbH
Bank name:
IBAN:
BIC/SWIFT:
./5
| Österreichische Forschungsförderungsgesellschaft mbH Xxxxxxxxxxx 0 0000 Xxxxxx |
Tel +43(0)5 7755-0 Fax+00 (0)0 0000-00000 xxx.xxx.xx, xxxxxx@xxx.xx FN 252263a HG Vienna |
| Page 5 | Project no. 832915/30000 TICK/SAI |
8 Reporting obligations
| 8.1 | The funding recipient must report the implementation of the funded project by submitting technical reports (interim and final reports) and settlements to the FFG according to point 3 of the General Funding Conditions. Reporting and accounting must take place via eCall (xxxxx://xxxxx.xxx.xx). Use of the forms defined in eCall is mandatory. Further documents must be made available to the FFG on request. |
9 Contract changes
| 9.1 | Changes to the current contract can be only made in written form. This applies also to a departure from this provision. |
| 9.2 | If necessary, subsequent changes to the agreed conditions and requirements can be made under special circumstances by mutual agreement in the form of written additional agreements, after reconsideration by the advisory board. |
10 Liability
| 10.1 | The funding recipient must be liable without limit to the FFG for adherence to all contractual conditions. The funding recipient is also liable for the behavior of third parties for whom he/she is responsible (e.g. owners, corporate bodies, etc.). The funding recipient indemnifies and holds the FFG harmless against the claims of third parties. |
11 Severability clause
| 11.1 | If a provision of this funding contract proves ineffective, the effectiveness of the remaining provisions of the funding contract are not affected. The contracting parties undertake to replace an ineffective provision by a provision that comes closest to the purpose of the contract. |
12 Applicable law
| 12.1 | This contract and all its annexes are subject to Austrian law excluding the reference provisions of the Austrian IPRG [International Private Law Act]. |
13 Jurisdiction
| 13.1 | The competent court in Vienna has jurisdiction in all litigation arising from the granting of funds. The FFG also retains the right to xxx the funding recipient in his/her general jurisdiction. |
14 Contract components
| 14.1 | The following documents are the integral elements of the funding contract: |
| • | the funding request (“Development of human monoclonal antibody based product against severe hospital associated bacterial infections”) in the version of 5/12/2011, submitted via eCall |
| • | General funding conditions for funding contracts in the current version (1/26/2009) |
| • | FFG basis program guidelines in the current version (2/3/2011) |
./6
| Österreichische Forschungsförderungsgesellschaft mbH Xxxxxxxxxxx 0 0000 Xxxxxx |
Tel +43(0)5 7755-0 Fax+00 (0)0 0000-00000 xxx.xxx.xx, xxxxxx@xxx.xx FN 252263a HG Vienna |
| Page 6 | Project no. 832915/30000 TICK/SAI |
| • | Guidelines for handling of project costs in funding requests and reports for projects with funding contracts according to FTE and FFG guidelines, version 1.2 |
| 14.2 | The following are regarded as the legal basis of this funding contract: |
| • | Österreichische Forschungsförderungsgesellschaft mbH establishment act (research funding, structure reform act) in the currently applicable version |
| • | the guidelines for the Österreichische Forschungsförderungsgesellschaft mbH for the funding of research, technology, development and innovation (FFG guidelines GZ: BMVIT-609.986/0005- 111/12/2008 and BMWA-98.310/0032-C1/10/2008) |
The funding recipient confirms his/her awareness of all contract components and accepts them without reservation.
It is hereby noted that the objective funding offer must be deemed as revoked, if the funding recipient does not return it signed to the FFG within 3 months.
For the funding donor:
Österreichische Forschungsförderungsgesellschaft mbH (FFG)
[seal:]
Austrian Research Promotion Agency mbH (FFG)
Vienna, 7/1/2011
| /s/ Dr. Xxxxxxxxx Egerth-Stadlhuber |
/s/ Xx. Xxxxx Pseiner | |||
| Dr. Xxxxxxxxx Egerth-Stadlhuber Managing Director |
Xx. Xxxxx Pseiner Managing Director |
Funding recipient
Vienna , on September 20, 2011
/s/ Xx. Xxxxxx Xxxx
(Add company signature, name and position in block letters, company stamp)
XX. XXXXXX XXXX,
Managing Director
ARSANIS
Biosciences GmbH
MarxBox
Xxxxxx-Xxxxxxxxxx-Xxxxx 0
0000 Xxxxxx
./7
| Österreichische Forschungsförderungsgesellschaft mbH Xxxxxxxxxxx 0 0000 Xxxxxx |
Tel +43(0)5 7755-0 Fax+00 (0)0 0000-00000 xxx.xxx.xx, xxxxxx@xxx.xx FN 252263a HG Vienna |
| Page 7 | Project no. 832915/30000 TICK/SAI |
Attachments:
Guidelines for the Österreichische Forschungsförderungsgesellschaft mbH for funding of research, technology, development and innovation (FFG guidelines) on link xxxx://xxx.xxx.xx/xxxxxxx/xxxxxxxxxxxxxxxxxx Allgemeine Förderungsbedingungen für Förderungsverträge in der geltenden Fassung (1/26/2009)
FFG basis program guidelines in the current version (2/3/2011)
Guidelines for handling of project costs in funding requests and reports for projects with funding contracts according to FTE and FFG guidelines, version 1.2
| Österreichische Forschungsförderungsgesellschaft mbH Xxxxxxxxxxx 0 0000 Xxxxxx |
Tel +43(0)5 7755-0 Fax+00 (0)0 0000-00000 xxx.xxx.xx, xxxxxx@xxx.xx FN 252263a HG Vienna |
| ARSANIS Biosciences GmbH Attention Xx. Xxxxxx Xxxx Xxxxxx-Xxxxxxxxxx-Xxxxx 0 0000 Xxxxxx |
Account statement of 12/31/2011
Project 832915
Development of human monoclonal antibody based product against severe hospital associated bacterial infections
| Account no.: |
00000000 | |||
| Financial year: |
2011 | |||
| Redemption amount (EUR): |
515,357.00 | |||
| Redemption date: |
6/30/2020 | |||
| Interest rate: |
2.00 | % |
| Balance on 12/31/2010 (EUR) |
0.00 | |||
| Document date |
Posting text |
Transaction amount (EUR) | ||
| 10.13.2011 | 832915 DA rate BP basis | -264.500,00 | ||
| 12.01.2011 | 832915 ZNS [interest] 2.0% on 12/31/2011 | -1.165,00 | ||
| 12.28.2011 | 832915 ZNS [interest] 2.0% on 12/31/2011 | 1.165,00 | ||
| Total debits (EUR) | 265,665.00 | |||
| Total credits (EUR) | 165,665.00 | |||
| Balance on 12/31/2011 (EUR) | -264,500.00 | |||
| Österreichische Forschungsförderungsgesellschaft mbH Xxxxxxxxxxx 0 0000 Xxxxxx |
Tel +43(0)5 7755-0 Fax+00 (0)0 0000-00000 xxx.xxx.xx, xxxxxx@xxx.xx FN 252263a HG Vienna |
| ARSANIS Biosciences GmbH Attention Xx. Xxxxxx Xxxx Xxxxxx-Xxxxxxxxxx-Xxxxx 0 0000 Xxxxxx |
Account statement on 12/31/2012
Project 832915
Development of human monoclonal antibody based product against severe hospital associated bacterial infections
| Account no.: |
00000000 | |||
| Financial year: |
2012 | |||
| Redemption amount (EUR): |
515,357.00 | |||
| Redemption date: |
6/30/2020 | |||
| Interest rate: |
2.00 | % |
| Balance on 12/31/2011 (EUR) |
-264,500.00 | |||
| Document date |
Posting text |
Transaction amount (EUR) | ||
| 02.09.2012 | 832915 DA rate 2 BP basis | -158.700,00 | ||
| 06.01.2012 | 832915 ZNS [interest] 2.0% on 6/30/2012 | -3.930,00 | ||
| 07.02.2012 | 832915 ZNS [interest] 2.0% on 6/30/2012 | 3.930,00 | ||
| 08.23.2012 | 832915 DA rate 3 | -92.157,00 | ||
| 12.03.2012 | 832915 ZNS [interest] 2.0% on 12/31/2012 | -4.996,00 | ||
| 12.27.2012 | 832915 ZNS [interest] 2.0% on 12/31/2012 | 4.996,00 | ||
| Total debits (EUR) | 259,783.00 | |||
| Total credits (EUR) | 8,926.00 | |||
| Balance on 12/31/2012 (EUR) | -515,357.00 | |||
| Österreichische Forschungsförderungsgesellschaft mbH Xxxxxxxxxxx 0 0000 Xxxxxx |
Tel +43 (0)5 7755-0 Fax+00 (0)0 0000-00000 xxx.xxx.xx, xxxxxx@xxx.xx FN 252263a HG Vienna |
| ARSANIS Biosciences GmbH Attention Xx. Xxxxxx Xxxx Xxxxxx-Xxxxxxxxxx-Xxxxx 0 0000 Xxxxxx |
Account statement on 12/31/2013
Project 832915
Development of human monoclonal antibody based product against severe
hospital associated bacterial infections
| Account no.: |
00000000 | |||
| Financial year: |
2013 | |||
| Redemption amount (EUR): |
515,357.00 | |||
| Repayment date: |
6/30/2020 | |||
| Interest rate: |
2.00 | % |
| Balance on 12/31/2012 (EUR) |
•515,357.00 | |||
| Document date |
Posting text |
Transaction amount (EUR) | ||
| 06.03.2013 | 832915 ZNS [interest] 2.0% on 6/30/2013 | -5.186,00 | ||
| 07.01.2013 | 832915 ZNS [interest] 2.0% on 6/30/2013 | 5.186.0 | ||
| 12.02.2013 | 832915 ZNS [interest] 2.0% on 12/31/2013 | -5.272,00 | ||
| 12.30.2013 | 832915 ZNS [interest] 2.0% on 12/31/2013 | 5.272,00 | ||
| Total debits (EUR) | 10,458.00 | |||
| Total credits (EUR) | 10,458.00 | |||
| Balance on 12/31/2012 (EUR) | -515,357.00 | |||
| Österreichische Forschungsförderungsgesellschaft mbH Xxxxxxxxxxx 0 0000 Xxxxxx |
Tel +43 (0)5 7755-0 Fax+00 (0)0 0000-00000 xxx.xxx.xx, xxxxxx@xxx.xx FN 252263a HG Vienna |
| ARSANIS Biosciences GmbH Attention Xx. Xxxxxx Xxxx Xxxxxx-Xxxxxxxxxx-Xxxxx 0 0000 Xxxxxx |
Account statement on 12/31/2014
Project 832915
Development of human monoclonal antibody based product against severe hospital associated bacterial infections
| Account no.: |
00000000 | |||
| Financial year: |
2014 | |||
| Redemption amount (EUR): |
515,357.00 | |||
| Redemption date: |
6/30/2020 | |||
| Interest rate: |
2.00 | % |
| Balance on 12/31/2013 (EUR) |
-515,357.00 | |||
| Document date |
Posting text |
Transaction amount (EUR) | ||
| 06.02.2014 | 832915 ZNS [interest] 2.0% on 6/30/2014 | -5.186,00 | ||
| 06.30.2014 | 832915 ZNS [interest] 2.0% on 6/30/2014 | 5.186,00 | ||
| 12.01.2014 | 832915 ZNS [interest] 2.0% on 12/31/2014 | -5.272,00 | ||
| 12.31.2014 | 832915 ZNS [interest] 2.0% on 12/31/2014 | 5.272,00 | ||
| Total debits (EUR) | 10,458.00 | |||
| Total credits (EUR) | 10,458.00 | |||
| Balance on 12/31/2014 (EUR) | -515,357.00 | |||
| Österreichische Forschungsförderungsgesellschaft mbH Xxxxxxxxxxx 0 0000 Xxxxxx |
Tel +43 (0)5 7755-0 Fax+00 (0)0 0000-00000 xxx.xxx.xx, xxxxxx@xxx.xx FN 252263a HG Vienna |
| ARSANIS Biosciences GmbH Attention Xx. Xxxxxx Xxxx Xxxxxx-Xxxxxxxxxx-Xxxxx 0 0000 Xxxxxx |
Account statement on 12/31/2014
Project 832915
Development of human monoclonal antibody based product against severe
hospital associated bacterial infections
| Account no.: |
00000000 | |||
| Financial year: |
2015 | |||
| Redemption amount (EUR): |
515,357.00 | |||
| Redemption date: |
6/30/2020 | |||
| Interest rate: |
2.00 | % |
| Balance on 12/31/2014 (EUR) |
-515,357.00 | |||
| Document date |
Posting text |
Transaction amount (EUR) | ||
| 06.01.2015 | 832915 ZNS [interest] 2.0% on 6/30/2015 | -5.186,00 | ||
| 06.30.2015 | 832915 ZNS [interest] 2.0% on 6/30/2015 | 5.186,00 | ||
| Total debits (EUR) | 5,186.00 | |||
| Total credits (EUR) | 5,186.00 | |||
| Balance on 10/31/2015 (EUR) | -515,357.00 | |||
| Österreichische Forschungsförderungsgesellschaft mbH Xxxxxxxxxxx 0 0000 Xxxxxx |
Tel +43 (0)5 7755-0 Fax+00 (0)0 0000-00000 xxx.xxx.xx, xxxxxx@xxx.xx FN 252263a HG Vienna |
